NASDAQ:INDP Indaptus Therapeutics 5/14/2025 Earnings Report $0.44 +0.02 (+5.69%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$0.45 +0.01 (+2.05%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Indaptus Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.41Beat/MissBeat by +$0.09One Year Ago EPSN/AIndaptus Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIndaptus Therapeutics Announcement DetailsQuarterDate5/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14 at 8:00 AM | globenewswire.comIndaptus Therapeutics (INDP) to Release Quarterly Earnings on WednesdayMay 12 at 3:39 AM | americanbankingnews.comFed’s New Plan: They Could Freeze Your AccountThe Fed's Plan to Control Your Money Is Live! While everyone is focused on tariffs and inflation, the Federal Reserve is quietly rolling out a new program that could give them unprecedented control over your bank account. This isn't a rumor—it's all laid out in Federal Reserve Docket No. OP-1670, a 93-page document that reveals their plan to monitor and control your finances to shield yourself. In this free Wealth Defense Guide, we'll show you 3 simple steps to shield your money from the Fed's overreach and keep your savings safe.May 14, 2025 | Priority Gold (Ad)Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development SummitMay 8, 2025 | globenewswire.comIndaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 SummitMarch 25, 2025 | globenewswire.comIndaptus Therapeutics reports new data on Phase 1 trial of Decoy20March 21, 2025 | markets.businessinsider.comSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP), a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles AppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upcoming Earnings Copart (5/15/2025)NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
